Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy
© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
Canavan disease is a leukodystrophy caused by ASPA mutations that diminish oligodendroglial aspartoacylase activity, and is characterized by markedly elevated brain concentrations of the aspartoacylase substrate N-acetyl-l-aspartate (NAA) and by astroglial and intramyelinic vacuolation. Astroglia express NaDC3 (encoded by SLC13A3), a sodium-coupled transporter for NAA and other dicarboxylates. Astroglial conditional Slc13a3 deletion in aspartoacylase-deficient Canavan disease model mice ("CD mice") reversed brain NAA elevation and improved motor function. These results demonstrate that astroglial NaDC3 contributes to brain NAA elevation in CD mice, and suggest that suppressing astroglial NaDC3 activity would ameliorate human Canavan disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Annals of clinical and translational neurology - 11(2024), 4 vom: 22. Apr., Seite 1059-1062 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hull, Vanessa L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
30KYC7MIAI |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/acn3.52010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367726572 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367726572 | ||
| 003 | DE-627 | ||
| 005 | 20240423232117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acn3.52010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1384.xml |
| 035 | |a (DE-627)NLM367726572 | ||
| 035 | |a (NLM)38282243 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hull, Vanessa L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a Canavan disease is a leukodystrophy caused by ASPA mutations that diminish oligodendroglial aspartoacylase activity, and is characterized by markedly elevated brain concentrations of the aspartoacylase substrate N-acetyl-l-aspartate (NAA) and by astroglial and intramyelinic vacuolation. Astroglia express NaDC3 (encoded by SLC13A3), a sodium-coupled transporter for NAA and other dicarboxylates. Astroglial conditional Slc13a3 deletion in aspartoacylase-deficient Canavan disease model mice ("CD mice") reversed brain NAA elevation and improved motor function. These results demonstrate that astroglial NaDC3 contributes to brain NAA elevation in CD mice, and suggest that suppressing astroglial NaDC3 activity would ameliorate human Canavan disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Aspartic Acid |2 NLM | |
| 650 | 7 | |a 30KYC7MIAI |2 NLM | |
| 650 | 7 | |a Slc13a3 protein, mouse |2 NLM | |
| 700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a McDonough, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Meina |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Travis |e verfasserin |4 aut | |
| 700 | 1 | |a Al Ramel, Najmah |e verfasserin |4 aut | |
| 700 | 1 | |a Dehghani, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Fuzheng |e verfasserin |4 aut | |
| 700 | 1 | |a Pleasure, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and translational neurology |d 2014 |g 11(2024), 4 vom: 22. Apr., Seite 1059-1062 |w (DE-627)NLM234874031 |x 2328-9503 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:4 |g day:22 |g month:04 |g pages:1059-1062 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acn3.52010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 4 |b 22 |c 04 |h 1059-1062 | ||